Yawei Du
Tianjin Medical University Cancer Institute and Hospital(CN)Nanjing University(CN)
Publications by Year
Research Areas
Hepatocellular Carcinoma Treatment and Prognosis, Ferroptosis and cancer prognosis, Hepatitis C virus research, Pancreatic and Hepatic Oncology Research, Cancer Cells and Metastasis
Most-Cited Works
- → Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression(2023)84 cited
- → A Five‐Gene Signature for Recurrence Prediction of Hepatocellular Carcinoma Patients(2020)10 cited
- → CD44 identified as a diagnostic biomarker for highly malignant CA19-9 negative pancreatic cancer(2025)5 cited
- → Discovery of novel thiazolylhydrazone derivatives as potent anti-cancer agents inducing ferroptosis via direct NRF2 inhibition(2025)2 cited
- → Gene expression signature comparison for solid tumor chemotherapy.(2011)
- → <span>Comparison outcome&nbsp;of&nbsp;transarterial&nbsp;chemoembolization&nbsp;combined with immune checkpoint inhibitors plus bevacizumab or lenvatinib as first-line therapy for advanced hepatocellular carcinoma</span>(2024)
- → 1498P A study on exploring the correlation between benefits of immunotherapy in advanced hepatocellular carcinoma (HCC) based on multi-omics approaches(2025)